First, ultimately, over half of GCA patients in GiACTA trial treated with tocilizumab still flared over three years, yet had long-term remission.[1,12,13] Naturally, identifying these two subgroups is required to guide clinical practice, but this effort has not yet been successful.[14] Second, tocilizumab is a potent suppressor of acute phase reactants and can rapidly normalize C-creative protein (CRP) and erythrocyte sedimentation rate (ESR) but not necessarily suppress the underlying inflammation of vasculitis. This evidence concerns the gene CRP and temporal arteritis.